Nelarabine

Drug Profile

Nelarabine

Alternative Names: 506U; 506U78; Arranon; Atriance; C 506; Compound 506; GW 506U; GW 506U78; Nelzarabine

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer National Cancer Institute (USA); Novartis
  • Class Antineoplastics; Arabinonucleosides; Small molecules
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia; T cell lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia; T cell lymphoma
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 04 Jun 2015 Nelarabine is still in phase III development for Acute lymphoblastic leukaemia (Combination therapy, First-line therapy) and T-cell lymphoma (Combination therapy, First-line therapy) in Australia, Canada, New Zealand, Switzerland and USA
  • 04 Jun 2015 Nelarabine is still in phase I/II development for Acute lymphoblastic leukaemia (Combination therapy, Second-line therapy or greater) and T-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA, Canada, Australia, Austria, France, Italy and Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top